Evidence map›Paper›PMID 24334175›Full record

Trial reportCirculation2014

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl and 1 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 579 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
579citing papers in PubMed, 12 pooled it
50.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02911792 phase4completedstarted 2016, after this paper: background citation

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Ran2016Enrolled72Registered outcomes1Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armsdapagliflozin, Glipizide 5 MG, Metformin
PMID 2030719PMID 20496053PMID 21606218PMID 2190281PMID 21940401PMID 22773704PMID 24334174PMID 24927646PMID 3011862PMID 3712971PMID 6940408PMID 7036732other papers from this trial
Open the trial in the graph
NCT03917758 naunknown statusstarted 2018, after this paper: background citation

Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study

Ran2018Enrolled30Registered outcomes24Posted comparisons0ConditionsArterial Hypertension, Body Weight Changes, Diabetes Mellitus, Type 2ArmsSGLT2 inhibitor
PMID 27822054PMID 26161452PMID 23735727PMID 23668478PMID 23624546PMID 27802313PMID 26378978PMID 26321369other papers from this trial
Open the trial in the graph
NCT01392560 phase2completednot on this map

An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)

TypeinterventionalSponsorBoehringer IngelheimRan2011 to 2012Enrolled52ConditionsDiabetes Mellitus, Type 1ArmsBI 10773
3 · Its place in the literature

Who cites it

579 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial

519 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

David Z I CherneyDepartment of Medicine, Division of Nephrology (D.Z.I.C., M.M., V.L., A.L.) and the Department of Medicine, Division of Endocrinology (B.A.P.), Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; Boehringer Ingelheim Canada Ltd./Ltée, Burlington, Ontario, Canada (N.S.); Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (N.M.F., M.v.E.); and Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany (H.J.W., O.E.J., U.C.B.).
Bruce A Perkins
Nima Soleymanlou
Maria Maione
Vesta Lai
Alana Lee
Nora M Fagan
Hans J Woerle
Odd Erik Johansen
Uli C Broedl
Maximilian von Eynatten
Boehringer Ingelheim (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks' sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D). METHODS AND

resultsInulin (glomerular filtration rate; GFR) and paraaminohippurate (effective renal plasma flow) clearances were measured in individuals stratified based on having hyperfiltration (T1D-H, GFR ≥ 135 mL/min/1.73m(2), n=27) or normal GFR (T1D-N, GFR 90-134 mL/min/1.73m(2), n=13) at baseline. Renal function and circulating levels of renin-angiotensin-aldosterone system mediators and NO were measured under clamped euglycemic (4-6 mmol/L) and hyperglycemic (9-11 mmol/L) conditions at baseline and end of treatment. During clamped euglycemia, hyperfiltration was attenuated by -33 mL/min/1.73m(2) with empagliflozin in T1D-H, (GFR 172±23-139±25 mL/min/1.73 m(2), P<0.01). This effect was accompanied by declines in plasma NO and effective renal plasma flow and an increase in renal vascular resistance (all P<0.01). Similar significant effects on GFR and renal function parameters were observed during clamped hyperglycemia. In T1D-N, GFR, other renal function parameters, and plasma NO were not altered by empagliflozin. Empagliflozin reduced hemoglobin A1c significantly in both groups, despite lower insulin doses in each group (P≤0.04).

conclusionsIn conclusion, short-term treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjects with T1D, likely by affecting tubular-glomerular feedback mechanisms. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01392560.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAdultBenzhydryl CompoundsDiabetes Mellitus, Type 1FemaleGlomerular Filtration RateGlucose Clamp TechniqueGlucosidesHemodynamicsHumansKidneyMaleSodium-Glucose Transporter 2Treatment OutcomeYoung AdultBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsdiabetes mellitusdiabetic nephropathieshypertension, renalnitric oxiderenin-angiotensin systemSGLT2 protein

Identifiers

PMID24334175
OpenAlexW1990025047

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.